ImmunoPrecise Antibodies collaborates with FIND to help advance new TB diagnostic test

VICTORIA, February 19, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration project with the Foundation for Innovative New Diagnostics (FIND) where IPA developed rabbit monoclonal antibodies (mAbs) for assessment in FIND’s sensitive new immunoassay diagnostic test for tuberculosis (TB). IPA developed rabbit monoclonal antibodies, using its B cell Select platform, that recognize lipoarabinomannan (LAM), a lipopolysaccharide target and biomarker for TB that can be excreted in the urine of individuals with the disease. Two of these antibodies, when combined with others to form capture-detection pairs and a sensitive chemical detection reagent, were highly specific for LAM and sensitive enough to detect LAM in urine samples.